The University of Southern California's Alfred E. Mann Institute Innovation Fund has made an investment in Oryn Therapeutics. The amount was not disclosed.
The investment supports Oryn's work toward nominating a development candidate from its next-generation Orynotide™ platform, the IND-enabling studies that follow, and continued buildout of the platform itself.
Research that began at USC
Oryn's science originated in the laboratory of Michael Selsted, MD, PhD, Professor of Pathology and the Seth MacFarlane Professor of Immunopathology at the Keck School of Medicine of USC. Dr. Selsted is Oryn's scientific founder and interim Chief Scientific Officer.
His laboratory discovered theta-defensins, circular peptides produced by Old World monkeys and absent in humans. Oryn's Orynotides™ are engineered macrocyclic peptides built on that work, designed for autoimmune, inflammatory and fibro-inflammatory diseases.
Oryn was founded on decades of pioneering research in Dr. Mike Selsted's laboratory at USC, making it especially meaningful to welcome USC as an investor. We are advancing a new class of macrocyclic medicines with the potential to transform the treatment of immune mediated diseases, where therapeutic options often rely on broad immunosuppression. Our approach aims to move beyond suppressing the immune system toward reprogramming disease-driving inflammatory pathways while preserving protective immune function. USC's support brings us closer to translating this vision into reality as we advance toward development candidate nomination and the clinic, while building a platform with the potential to address complex diseases beyond the reach of conventional therapeutics. Guy Rosenthal, PhD, MBA, President and CEO, Oryn Therapeutics
Leadership
Oryn is led by President and Chief Executive Officer Guy Rosenthal, PhD, MBA, with Paul Carrington, PhD, Senior Vice President, Discovery & Early Development, and Prof. Michael Selsted as scientific founder and interim Chief Scientific Officer. Paul Sekhri is Executive Chair of the board of directors, which also includes Nina Kjellson, General Partner at Canaan, Gary Phillips, MD, and investor board members Mark Armenante and Young Sohn.
Source
Read USC's announcement: From the Selsted Lab to the Clinic: USC Invests in Oryn Therapeutics, USC Office of Research and Innovation, November 19, 2026.
